Spherium Biomed   Report issue

For profit Phase 1 Phase 2
Founded: Barcelona Spain (2009)
Status: Defunct (2020)

Organization Overview

First Clinical Trial
2015
NCT02630004
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Spherium Biomed

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Pain (Phase 2)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Head and Neck Neoplasms (Phase 2)

Joint Diseases (Phase 2)

Mucositis (Phase 2)

Myalgia (Phase 2)

Signs and Symptoms (Phase 1)

Stomatitis (Phase 2)

Temporomandibular Joint Disorders (Phase 2)

Temporomandibular Joint Dysfunction Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 7